202 related articles for article (PubMed ID: 32311221)
1. Opportunistic infections complicating immunotherapy for non-small cell lung cancer.
Liu Z; Liu T; Zhang X; Si X; Wang H; Zhang J; Huang H; Sun X; Wang J; Wang M; Zhang L
Thorac Cancer; 2020 Jun; 11(6):1689-1694. PubMed ID: 32311221
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
[TBL] [Abstract][Full Text] [Related]
3. A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer.
Cathcart-Rake EJ; Sangaralingham LR; Henk HJ; Shah ND; Riaz IB; Mansfield AS
Clin Lung Cancer; 2020 Sep; 21(5):421-427.e2. PubMed ID: 32446852
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M
Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
[TBL] [Abstract][Full Text] [Related]
5. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
6. The Role of Immune-Related Adverse Events in Prognosis and Efficacy Prediction for Patients with Non-Small Cell Lung Cancer Treated with Immunotherapy: A Retrospective Clinical Analysis.
Sonehara K; Tateishi K; Araki T; Komatsu M; Yamamoto H; Koizumi T; Hanaoka M
Oncology; 2021; 99(5):271-279. PubMed ID: 33631764
[TBL] [Abstract][Full Text] [Related]
7. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
[TBL] [Abstract][Full Text] [Related]
8. The role of IL-6 in immunotherapy of non-small cell lung cancer (NSCLC) with immune-related adverse events (irAEs).
Ke W; Zhang L; Dai Y
Thorac Cancer; 2020 Apr; 11(4):835-839. PubMed ID: 32043828
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor-associated interstitial lung diseases correlate with better prognosis in patients with advanced non-small-cell lung cancer.
Sugano T; Seike M; Saito Y; Kashiwada T; Terasaki Y; Takano N; Hisakane K; Takahashi S; Tanaka T; Takeuchi S; Miyanaga A; Minegishi Y; Noro R; Kubota K; Gemma A
Thorac Cancer; 2020 Apr; 11(4):1052-1060. PubMed ID: 32096610
[TBL] [Abstract][Full Text] [Related]
10. Timing of resumption of immune checkpoint inhibitor therapy after successful control of immune-related adverse events in seven advanced non-small cell lung cancer patients.
Kashiwabara K; Fujii S; Tsumura S; Sakamoto K
Anticancer Drugs; 2020 Sep; 31(8):872-875. PubMed ID: 32796406
[TBL] [Abstract][Full Text] [Related]
11. Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review.
Zhang D; Zhang Y; Huang Y; Kong L; Yu J
Lung Cancer; 2020 Jan; 139():18-21. PubMed ID: 31704279
[TBL] [Abstract][Full Text] [Related]
12. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
13. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
14. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
15. The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
Sakata Y; Kawamura K; Ichikado K; Shingu N; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Iio M; Sekido Y; Nakano A; Sakagami T
Lung Cancer; 2019 Apr; 130():159-161. PubMed ID: 30885338
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy-Induced Airway Disease: A New Pattern of Lung Toxicity of Immune Checkpoint Inhibitors.
Mitropoulou G; Daccord C; Sauty A; Pasche A; Egger B; Aedo Lopez V; Letovanec I; Beigelman-Aubry C; Nicod LP; Lazor R
Respiration; 2020; 99(2):181-186. PubMed ID: 31914436
[TBL] [Abstract][Full Text] [Related]
17. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
18. Safety of current immune checkpoint inhibitors in non-small cell lung cancer.
Abdayem P; Planchard D
Expert Opin Drug Saf; 2021 Jun; 20(6):651-667. PubMed ID: 33393387
[No Abstract] [Full Text] [Related]
19. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer.
Nishiyama O; Shimizu S; Haratani K; Isomoto K; Tanizaki J; Hayashi H; Yamazaki R; Oomori T; Nishikawa Y; Sano A; Nakagawa K; Tohda Y
BMC Pulm Med; 2021 May; 21(1):155. PubMed ID: 33964920
[TBL] [Abstract][Full Text] [Related]
20. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.
Hasan Ali O; Berner F; Bomze D; Fässler M; Diem S; Cozzio A; Jörger M; Früh M; Driessen C; Lenz TL; Flatz L
Eur J Cancer; 2019 Jan; 107():8-14. PubMed ID: 30529903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]